中国癌症杂志 ›› 2016, Vol. 26 ›› Issue (10): 848-853.doi: 10.19401/j.cnki.1007-3639.2016.10.007

• 论著 • 上一篇    下一篇

ER阳性乳腺癌中Efp和Plk3蛋白表达相关性探讨

段佳君,邹天宁,张 季,刘德权   

  1. 云南省肿瘤医院/ 昆明医科大学第三附属医院乳腺外一科,云南 昆明 650118
  • 出版日期:2016-10-30 发布日期:2016-11-17
  • 通信作者: 段佳君 E-mail:zhuomiansohuji@163.com

Expression correlation between Efp and Plk3 in estrogen receptor-positive breast cancer

DUAN Jiajun, ZOU Tianyu, ZHANG Ji, LIU Dequan   

  1. Department of Mammary Surgery, Yunnan Cancer Hospital, Third Affiliated Hospital of Kunming Medical University, Kunming 650118, Yunnan Province, China
  • Published:2016-10-30 Online:2016-11-17
  • Contact: DUAN Jiajun E-mail: zhuomiansohuji@163.com

摘要: 背景与目的:长期以来,雌激素受体(estrogen receptor,ER)阳性乳腺癌患者对内分泌治疗耐药是临床上棘手的难题。目前研究表明,雌激素效应环指蛋白(estrogen-responsive finger protein,Efp)和polo样激酶3(polo-like kinase 3,Plk3)的表达与乳腺癌发展具有密切关系。该研究旨在探讨ER阳性乳腺癌中Efp和Plk3蛋白表达相关性,了解Efp和Plk3表达变化在耐药中的作用。方法:应用免疫组织化学SP法检测74例ER阳性乳腺癌组织中Efp和Plk3蛋白表达情况,结合临床资料进行分析。并采用实时荧光定量聚合酶链反应(real-time fluorescent quantitative polymerase chain reaction,RTFQ-PCR)及蛋白[质]印迹法(Western blot)检测ER阳性乳腺癌MCF-7细胞中Efp和Plk3的基因和蛋白表达变化。结果:74例ER阳性乳腺癌组织中Efp和Plk3蛋白表达与患者的临床病理特征未见任何关系(P>0.05),其中有51例(68.9%)患者Efp表达阳性和23例(31.1%)患者Plk3表达阳性,χ2检验分析结果显示,ER阳性乳腺癌组织中Efp和Plk3具有显著的负相关关系(χ2=8.837,P<0.05)。RTFQ-PCR检测结果显示,MCF-7细胞经雌激素刺激后Efp mRNA的表达显著增加,而Plk3 mRNA的表达无明显变化。Western blot检测结果显示,MCF-7细胞经雌激素和MG132刺激后,Efp的蛋白表达较MG132组显著增加,而Plk3蛋白表达明显下降。结论:在ER阳性乳腺癌患者中Efp和Plk3的蛋白表达呈负相关,Efp高表达可促进Plk3的蛋白降解,对内分泌耐药过程的形成可能产生一定影响。

关键词: 乳腺癌, 雌激素受体, 雌激素效应环指蛋白, Polo样激酶3, 耐药

Abstract: Background and purpose: Estrogen receptor (ER)-positive breast cancer always presents a dilemma for resistance to endocrine therapy in a long time. The recent studies showed that the expression of estrogenresponsive finger protein (Efp) and polo-like kinase 3 (Plk3) had a close relationship with breast cancer development. This study was to explore the expression correlation between Efp and Plk3 in ER-positive breast cancer in order to understand the influence of Efp and Plk3 on the drug resistance. Methods: The expression of Efp and Plk3 in 74 cases of ER-positive breast cancer was detected by SP immunohistochemistry. The clinical significance was then analyzed. Real-time fluorescent quantitative polymerase chain reaction (RTFQ-PCR) and Western blot were used to detect the expression of Efp and Plk3 in ER-positive MCF-7 cells. Results: No significant relationship was found between Efp and Plk3 expression and the clinicopathological features of 74 cases of ER-positive breast cancer (P>0.05). The number of cases whose Efp showed positive expression was 51 (68.9%), while the number of cases whose Plk3 showed positive expression was 23 (31.1%). Chi-square test analysis showed the expression of Efp and Plk3 was negatively correlated in 74 cases of ER-positive breast cancer (χ2=8.837, P<0.05). The result of RTFQ-PCR showed that the expression of Efp mRNA in MCF-7 cells was up-regulated by estrogen stimulation, whereas Plk3 mRNA was not changed. The result of Western blot showed that the expression of Efp protein in MCF-7 cells was increased by estrogen and MG132 stimulation, whereas Plk3 protein was decreased. Conclusion: The expression of the Efp protein is negatively correlated with Plk3 protein in ER-positive breast cancer. High expression of Efp may be involved in the resistance to endocrine therapy.

Key words: Breast cancer, Estrogen receptor, Estrogen-responsive finger protein, Polo-like kinase 3, Drug resistance